| 119.75 -1.42 (-1.17%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 149.58 | 1-year : | 156.39 |
| Resists | First : | 128.06 | Second : | 133.89 |
| Pivot price | 123.49  |
|||
| Supports | First : | 118.62 | Second : | 98.7 |
| MAs | MA(5) : | 120.52 |
MA(20) : | 125.01 |
| MA(100) : | 123.64 |
MA(250) : | 124.14 |
|
| MACD | MACD : | -1.9 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 18.1 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 149.25 | Low : | 102 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZBH ] has closed above bottom band by 21.9%. Bollinger Bands are 84.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 121.22 - 121.88 | 121.88 - 122.43 |
| Low: | 117.15 - 117.98 | 117.98 - 118.67 |
| Close: | 118.49 - 119.77 | 119.77 - 120.82 |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Thu, 25 Apr 2024
Zimmer Biomet Announces Successful Completion of World’s First Robotic-Assisted Shoulder Replacement Surgery ... - OrthoSpineNews
Wed, 24 Apr 2024
Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Tue, 23 Apr 2024
Zimmer Biomet Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Mon, 22 Apr 2024
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Mon, 22 Apr 2024
#7. Zimmer Biomet Holdings Inc (ZBH) | State | pdclarion.com - pdclarion.com
Sun, 21 Apr 2024
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now - Yahoo Lifestyle UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 205 (M) |
| Shares Float | 205 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 90.9 (%) |
| Shares Short | 4,730 (K) |
| Shares Short P.Month | 4,900 (K) |
| EPS | 4.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 60.7 |
| Profit Margin | 13.8 % |
| Operating Margin | 23.7 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 8.3 % |
| Qtrly Rev. Growth | 6.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 35.96 |
| EBITDA (p.s.) | 11.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,580 (M) |
| Levered Free Cash Flow | 1,140 (M) |
| PE Ratio | 24.53 |
| PEG Ratio | 2.1 |
| Price to Book value | 1.97 |
| Price to Sales | 3.32 |
| Price to Cash Flow | 15.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|